Sign In
Buy ARGX
$813.14
+10.97 (+1.37%)
At Close: Jun 03, 2026
argenx raises $1.0 billion in gross proceeds in a global offering
10:15pm, Tuesday, 02'nd Feb 2021
Regulated information — Inside information
argenx Issues Statement Concerning Efgartigimod
09:37am, Tuesday, 02'nd Feb 2021
-No observed elevation of cholesterol markers related to treatment with efgartigimod
argenx announces launch of proposed global offering
04:01pm, Monday, 01'st Feb 2021
Regulated information — Inside information
Regulated Information/Inside Information
Week In Review: China Biopharma Starts 2021 With Over $1 Billion In Deals And IPOs
03:16pm, Sunday, 10'th Jan 2021
Gracell Biotech completed a $209 million NASDAQ IPO for its next-gen CAR-T treatments. Zai Lab acquired greater China rights to an argenx SE novel treatment for autoimmune indications in a deal worth
argenx Announces 2021 Corporate Priorities and Highlights Recent Achievements Across Immunology Pipeline
01:00am, Friday, 08'th Jan 2021
Breda, the Netherlands – Jan. 8, 2021 – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cance
argenx and Zai Lab Announce Strategic Collaboration for Efgartigimod in Greater China
04:01pm, Wednesday, 06'th Jan 2021argenx to Present at 39th Annual J.P. Morgan Healthcare Conference
01:00am, Monday, 04'th Jan 2021
January 4, 2021 Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune di
argenx Enters Into Agreement To Acquire Priority Review Voucher
01:00am, Monday, 23'rd Nov 2020
November 23, 2020 Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune
argenx to Participate in Upcoming Virtual Investor Conferences
01:00am, Monday, 09'th Nov 2020
November 9, 2020 Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune d
argenx to Present at 2020 Wedbush PacGrow Healthcare Virtual Conference
05:00am, Tuesday, 04'th Aug 2020
August 4, 2020 Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune
argenx SE (ARGX) CEO Tim Van Hauwermeiren on Q2 2020 Results - Earnings Call Transcript
11:59am, Sunday, 02'nd Aug 2020
argenx SE (NASDAQ:ARGX) Q2 2020 Earnings Conference Call July 30, 2020 8:30 AM ET Company Participants Beth DelGiacco - Vice President, Investor Relations Tim Van Hauwermeiren - Chief Executive Office
argenx SE 2020 Q2 - Results - Earnings Call Presentation
03:58pm, Saturday, 01'st Aug 2020
The following slide deck was published by argenx SE in conjunction with their 2020 Q2 earnings call.
argenx reports half year 2020 financial results and provides second quarter business update
05:00am, Thursday, 30'th Jul 2020
* Biologics License Application for efgartigimod in generalized myasthenia gravis on track to be submitted to U.S. Food and Drug Administration by end of year * Full data from ADAPT trial to be pr
Earnings Preview: argenx
05:46pm, Wednesday, 29'th Jul 2020
On Thursday, July 30, argenx (NASDAQ: ARGX) will release its latest earnings report. Benzinga's outlook for argenx is included in the following report.Earnings and Revenue argenx EPS will likely be ne
